Manufacturing Chemist (MC) talks with Mark Hammond, Commercial Director at Aesica, about the many ways innovation can deliver measureable value across the entire process stream, gaining insight into the rapidly changing environment in which today’s pharmaceutical manufacturers are operating.
MC: How has the role of the contract manufacturer changed in recent years?
Hammond: It’s always been the case that contract development and manufacturing organisations (CDMOs) have had to stay flexible to meet the changing needs of the pharma industry. As Big Pharma has modified its business models, manufacturers have had to rapidly adapt to identify and meet gaps in the industry’s manufacturing capacity.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.